TriSalus Life Sciences (TLSI) vs Treace Medical Concepts (TMCI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TriSalus Life Sciences (TLSI) has outperformed Treace Medical Concepts (TMCI) over the past year, losing 14.8% versus a loss of 37.1%. Over five years, TLSI leads with a -58.3% price change compared with -84.1% for TMCI. TriSalus Life Sciences is the larger company by market cap ($256.2 million vs $253.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLSI | TMCI |
|---|---|---|
| Share price | $4.16 | $3.89 |
| Market cap | $256.15M | $252.98M |
| 1-day change | +0.73% | +0.39% |
| YTD return | -40.83% | +58.16% |
| 1-year return | -14.85% | -37.09% |
| 5-year return | -58.28% | -84.13% |
| EPS (TTM) | $-1.22 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.95 | $7.08 |
| 52-week low | $2.20 | $1.17 |
| Distance from 52-week high | -47.67% | -45.06% |
| Analyst consensus | none | none |
| Avg. price target upside | +150.00% | +41.39% |
| Average volume | 275.38K | 326.50K |
| Shares outstanding | 61.57M | 65.03M |
| Employees | 102 | 450 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLSI has outperformed TMCI by 22.2 percentage points over the past year.
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
About Treace Medical Concepts
TMCI stock →Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions.
Health Care · Medical/Dental Instruments · 450 employees
TLSI vs TMCI FAQ
Which is bigger, TriSalus Life Sciences or Treace Medical Concepts?
TriSalus Life Sciences (TLSI) is larger, with a market capitalization of $256.15M compared with $252.98M for Treace Medical Concepts (TMCI).
Which stock has performed better over the past year, TLSI or TMCI?
TLSI returned -14.85% over the past 12 months, compared with -37.09% for TMCI (price return, excluding dividends). Past performance does not predict future results.
Are TriSalus Life Sciences and Treace Medical Concepts in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for TriSalus Life Sciences and Medical/Dental Instruments for Treace Medical Concepts.